Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDxHealth SA ADR (MDXH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MDXH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.04
1 Year Target Price $6.04
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.4% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 171.26M USD | Price to earnings Ratio - | 1Y Target Price 6.04 |
Price to earnings Ratio - | 1Y Target Price 6.04 | ||
Volume (30-day avg) 6 | Beta -492297.9 | 52 Weeks Range 1.35 - 3.81 | Updated Date 08/29/2025 |
52 Weeks Range 1.35 - 3.81 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When Before Market | Estimate -0.1175 | Actual -0.15 |
Profitability
Profit Margin -34.98% | Operating Margin (TTM) -7.2% |
Management Effectiveness
Return on Assets (TTM) -7.92% | Return on Equity (TTM) -1552.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 222460775 | Price to Sales(TTM) 1.73 |
Enterprise Value 222460775 | Price to Sales(TTM) 1.73 | ||
Enterprise Value to Revenue 2.31 | Enterprise Value to EBITDA -2.73 | Shares Outstanding 49497300 | Shares Floating 35018869 |
Shares Outstanding 49497300 | Shares Floating 35018869 | ||
Percent Insiders 13.22 | Percent Institutions 43.66 |
Upturn AI SWOT
MDxHealth SA ADR
Company Overview
History and Background
MDxHealth SA ADR was founded in 2003 and is a molecular diagnostics company that develops and commercializes epigenetic tests for cancer assessment. It focuses on providing clinically useful information to personalize cancer treatment decisions. The company has evolved from early research to commercializing its tests through a global network.
Core Business Areas
- Urology: Provides genomic tests for prostate cancer diagnosis and management, focusing on avoiding unnecessary biopsies and guiding treatment decisions.
- Oncology: Develops and commercializes tests to aid in the diagnosis and prognosis of other cancers, leveraging its epigenetic platform.
Leadership and Structure
MDxHealth SA ADR has a board of directors and an executive leadership team responsible for strategic direction and operations. Key leaders include the CEO and CFO, along with heads of research, commercial operations, and regulatory affairs. The organizational structure is designed to support research, development, and commercialization of its molecular diagnostic tests.
Top Products and Market Share
Key Offerings
- SelectMDx for Prostate Cancer: A urine-based molecular test that helps determine a patient's risk of high-grade prostate cancer to avoid unnecessary biopsies. Competitors include Exact Sciences (Oncotype DX Prostate) and Genomic Health (now part of Exact Sciences). Market share for SelectMDx is approximately 15-20% in the relevant testing segment, with revenue figures varying depending on quarterly reports.
- ConfirmMDx for Prostate Cancer: A tissue-based epigenetic test to assess if a negative biopsy truly rules out the presence of cancer to reduce repeat biopsies. Competitors include Myriad Genetics (Prolaris) and Genomic Health (Oncotype DX Prostate). Market share for ConfirmMDx is approximately 5-10% in the relevant testing segment, revenue varies based on quarterly reports.
Market Dynamics
Industry Overview
The molecular diagnostics market is experiencing rapid growth, driven by advancements in genomics and personalized medicine. The demand for more accurate and less invasive diagnostic tests is increasing, particularly in cancer.
Positioning
MDxHealth SA ADR is positioned as a specialist in epigenetic testing for cancer, providing clinically actionable information to improve patient outcomes. Its competitive advantage lies in its proprietary technology and its focus on specific areas within oncology.
Total Addressable Market (TAM)
The global molecular diagnostics market is estimated at $10-15 billion and growing. MDxHealth's position in the urology (prostate cancer) and oncology segments means they are targeting a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary epigenetic technology
- Focus on specific cancer segments
- Established commercial infrastructure
- Clinically validated tests
Weaknesses
- Limited product portfolio
- Reliance on reimbursement approvals
- Relatively small size compared to larger diagnostic players
- ADR structure can add complexity for US investors
Opportunities
- Expanding test menu into other cancer types
- Strategic partnerships with pharmaceutical companies
- Geographic expansion
- Increasing adoption of personalized medicine
Threats
- Competition from larger diagnostic companies
- Changes in reimbursement policies
- Technological advancements by competitors
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- EXAS
- MYGN
- HOLX
Competitive Landscape
MDxHealth SA ADR competes with larger diagnostic companies that have broader product portfolios. Its advantage is its focus on epigenetic testing and specific areas of oncology, allowing for specialized expertise.
Growth Trajectory and Initiatives
Historical Growth: The company's growth has been driven by increased adoption of its SelectMDx test and expansion into new markets.
Future Projections: Analyst estimates suggest continued revenue growth, driven by increasing adoption of its existing tests and potential new product launches.
Recent Initiatives: Recent initiatives include expansion of its sales force, development of new tests, and partnerships with key opinion leaders.
Summary
MDxHealth SA ADR is a molecular diagnostics company focused on cancer testing, particularly prostate cancer. Its strengths lie in its proprietary epigenetic technology and established commercial infrastructure. It needs to navigate competition from larger diagnostic firms and maintain reimbursement approvals. Future growth depends on expanding its test menu and strategic partnerships, with key risk lies in changing technological landscapes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be entirely accurate. Investment decisions should be made based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MDxHealth SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-04 | CEO & Executive Director Mr. Michael K. McGarrity | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 312 | Website https://mdxhealth.com |
Full time employees 312 | Website https://mdxhealth.com | ||
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.